Colin R Dormuth (Colin Dormuth)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 9

Top Venues

Pharmacoepidemiology and drug safety

Gastroenterology research and practice

The Journal of rheumatology

Expert opinion on drug safety

University of British Columbia

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of British Columbia Jul 01 2007

Canada

Associate Professor :: Anesthesiology, Pharmacology & Therapeutics

Partners Healthcare; Brigham and Women's Hospital Jan 01 2002 - Dec 31 2005

United States

Research Fellow :: Division of Pharmacoepidemiology and Pharmacoeconomics

British Columbia Ministry of Health Jan 01 2001 - Aug 31 2003

Canada

Senior Economist :: Pharmacare

Publications

Anat Fisher, Jason D Kim, Colin R Dormuth
Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study. Gastroenterology research and practice 2023 (2023)
Anat Fisher, Jason D Kim, Colin R Dormuth
Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study. Gastroenterology research and practice 2023 (2023)
Barbara J Mintzes, Ellen Reynolds, Priya Bahri, Lucy T Perry, Alice L Bhasale, Richard L Morrow, Colin R Dormuth
How do safety warnings on medicines affect prescribing? Expert opinion on drug safety 21 (10) (2022)
Anat Fisher, Jason D Kim, Greg Carney, Colin R Dormuth
Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept-a cohort study in British Columbia. BMC rheumatology 6 (1) (2022)
Anat Fisher, Jason D Kim, Colin R Dormuth
Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia-An interim report. Pharmacoepidemiology and drug safety 29 (7) (2020)
Anat Fisher, Marie Hudson, Robert W Platt, Colin R Dormuth, null null
Tofacitinib Persistence in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study. The Journal of rheumatology 48 (1) (2020)
Colin R Dormuth, Anat Fisher, Greg Carney
A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia. Pharmacoepidemiology and drug safety 29 (7) (2020)
Anat Fisher, Greg Carney, Ken L Bassett, K Malcolm Maclure, Colin R Dormuth
Policy-induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia. Pharmacoepidemiology and drug safety 28 (8) (2019)
Greg Carney, Malcolm Maclure, Ken Bassett, Suzanne Taylor, Colin R Dormuth
Identifying sequential episodes of pharmacotherapy as a method for assessing treatment failure in comparative effectiveness research. Pharmacoepidemiology and drug safety 29 (2) (2019)

Colin R Dormuth (Colin Dormuth)

Publication Activity (10 Years)

Top Topics

Top Venues